Portfolio Construction in Institutional Infrastructure Technology

The standard approach to private equity portfolio construction treats each investment as an independent position judged on its own merits. In institutional infrastructure technology, this approach systematically undervalues the strategic relationships between portfolio companies and overlooks the compounding effects of domain expertise built up across investments.

Institutional infrastructure technology occupies a distinctive position in the broader technology landscape. Unlike consumer technology, where network effects and winner-take-all dynamics dominate, institutional infrastructure markets are characterized by deep specialization, long sales cycles, high switching costs, and regulatory barriers to entry. These characteristics create investment opportunities with at its core different risk and return profiles than those found in consumer or general enterprise technology.

The most major difference is the durability of competitive advantages. A consumer technology company may build a large user base that erodes rapidly when a superior alternative emerges. An institutional infrastructure company that has embedded its platform within the regulatory compliance workflows of a major bank, or within the clinical trial management processes of a pharmaceutical company, has created a competitive position that is protected by the operational risk of migration. This durability allows for longer holding periods and more patient capital deployment, which in turn enables value creation strategies that would be impractical in faster-moving technology segments.

Portfolio construction in this context requires a framework that accounts for the relationships between investments across different infrastructure domains. A position in regulatory technology creates insights about the compliance requirements facing financial institutions, which informs the review of cybersecurity companies serving the same institutions. A position in medical technology provides visibility into the regulatory approval processes that affect computational biology companies. These informational synergies are not incidental; they are a structural feature of investing across related infrastructure domains.

The nine domains in which we invest were selected not only for their individual attractiveness but for the density of their interconnections. Regulatory technology and cybersecurity share common customers and common regulatory drivers. Decision intelligence and enterprise automation tackle complementary aspects of institutional operational efficiency. Climate technology and resilient logistics both respond to the structural shift toward supply chain transparency and sustainability reporting. These interconnections create a portfolio where expertise built up in one domain directly enhances review-based capability in adjacent domains.

Capital allocation across these domains follows a framework that balances three considerations: the absolute attractiveness of individual opportunities, the portfolio-level diversification benefit of adding exposure to a particular domain, and the informational value of a position in terms of enhancing our review-based capability across the broader portfolio. This third consideration is often the most difficult to quantify, but it is often the most important for long-term portfolio performance.

The holding period for institutional infrastructure investments is usually longer than for general technology investments, reflecting both the slower pace of value realization and the compounding nature of competitive advantages in these markets. A regulatory technology platform that has been embedded within its customers' operations for five years is sharply more valuable than one that has been embedded for two years, not because the technology has improved but because the depth of integration and the cost of switching have increased. This dynamic rewards patience and penalizes premature exits.

Risk management in an institutional infrastructure portfolio focuses on a different set of concerns than in a general technology portfolio. The main risks are not technological obsolescence or competitive disruption but regulatory change, customer concentration, and integration complexity. A regulatory change that eliminates a compliance requirement can undermine the core value of a platform built to tackle that requirement. A portfolio company that derives a large share of its revenue from a small number of institutional customers faces concentration risk that is difficult to mitigate in the short term. And the complexity of integrating institutional infrastructure platforms with customers' existing systems creates rollout risk that can delay value realization.

Our approach to managing these risks is rooted in the same multi-scenario review-based framework that we apply to individual investments. At the portfolio level, we construct scenarios that model the impact of correlated risks across multiple positions, such as a broad regulatory reform that affects companies across several domains at once, or a macroeconomic downturn that causes institutional customers to delay technology investments across the board. This portfolio-level scenario review ensures that our overall risk exposure remains within acceptable bounds even under adverse conditions.